ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO766

Long Term Effects of Expanded Hemodialysis (HDx) on Clinical and Laboratory Parameters in a Large Cohort of Dialysis Patients

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Bunch, Alfonso, RTS, Bogota, Colombia
  • Nilsson, Lars-Goran, Baxter International Inc., Lund, Sweden
  • Vesga, Jasmin, RTS, Bogota, Colombia
  • Ardila, Freddy, RTS, Bogota, Colombia
  • Zuniga, Eduardo, RTS, Bogota, Colombia
  • Alarcon, Juan, RTS, Bogota, Colombia
  • Suarez, Adriana Marcela, RTS, Bogota, Colombia
  • Sanchez, Ricardo, Universidad Nacional de Colombia, Bogotá, Colombia
  • Sanabria, Mauricio, RTS Baxter, Bogota, Colombia
Background

Expanded hemodialysis (HDx) enabled by medium cut off membrane provides clearance of large middle molecules which have been linked to inflammation, immune modulation and atherosclerosis. The long term effects of HDx on serum levels of small solutes and albumin has not been investigated in large cohort of patients.

Methods

Multicenter prospective study in prevalent hemodialysis patients, older than 18 years old; enrolled from September 1 to November 30 of 2017, and converted to HDx using Theranova 400 (3 sessions per week, 4 hours per session, same heparin dose) . Albumin assay used was bromocresol blue with laboratory reference values between 3,5 gr/dl – 5,1 gr/dl
Measurements were done at baseline, week 2, and month 1,2,3,4,5,6; descriptive statistics and ANOVA were used.

Results

We analyzed data on 524 patients, 61.6% ( n=323) men, mean age 60.1 years (SD=15.3), dialysis vintage was 5.4 years ( SD=5.01).
We did not observe clinically significant differences in laboratory variables after 6 months of intervention with expanded hemodialysis; details are presented in Table 1.

We found an initial small decrease in serum albumin level which stabilized and within the normal range per our laboratory references. See Table 1

Dialysis performans adequacy (Kt/V) was achieved. No clinically significant differences in laboratory values at 6 months with HDx was observed (Table 2).

Conclusion

The expended hemodialysis (HDx) shows a very good safety and performance profile during the first three months of use.

Funding

  • Commercial Support